Pharmaceutical manufacturers should consider entering into value-based contracts with payers as they work to demonstrate the efficacy of their products, according to an MMIT report.
While entering into such a contract, however, it’s vital for drugmakers to take in the different definitions of value as they prepare their proposals early on in the drug development process.
Deloitte Consulting LLP’s Joe Coppola says value mapping can guide manufacturers to discovering value definitions and payers’ requirements.
“A standalone Medicare Part D plan has very different priorities than an integrated health system,” Precision for Value Executive Vice President Larry Blandford says.
To read more on MMIT, click here.